



---

CONFIDENTIAL

---



**Randel E. Richner, BSN, MPH**  
**President & Founder, Neocure Group, LLC**

### *About*

---

Randel Richner founded Neocure Group in June 2006, a consulting firm specializing in reimbursement, health policy, economics, and government advocacy support for biopharmaceutical and medical technology companies. Prior to founding the Neocure Group, Richner was Vice President, Global Government Affairs, Reimbursement and Outcomes Planning for Boston Scientific Corporation (BSC) for 9 years. At Boston Scientific, Richner built a global reimbursement and outcomes strategic process for new and existing less invasive medical technologies for BSC product platforms. During this time, she was actively engaged in national and international policy and legislative arenas as an advocate for the benefits of innovative medical technology, FDA, regulatory, international trade and payment issues.

Richner has been a leader in policy initiatives in Washington with Congress and the Center for Medicare and Medicaid Services (CMS). She served on a four-year term as the first industry representative to the Executive Committee (EC) of the Medicare Coverage Advisory Committee (MCAC), contributing to the development of national coverage and MCAC process guidelines. In 2007, she was reappointed to MedCAC (renamed) for a 2 year term. She is a frequent contributor on policy panels on health care issues related to the technology industry, such as an Institute of Medicine (IOM) special committee on cost-effectiveness and post-market surveillance in 2005. In 2006, Richner was appointed to the College of Fellows of the American Institute of Medical and Biological Engineers (AIMBE), selected to be a



---

CONFIDENTIAL

---

National Institute of Health Commercialization Program (NIH-CAP) Advisor; named to the Executive Advisory Board of the Center for the Evaluation of Value and Risk in Health (CEVRH) Tufts New England Medical Center, appointed to serve on the Executive Advisory Board to the Dean of the University of Michigan's School of Public Health and the University of Michigan Ross Business School Healthcare Life Sciences Corporate Advisory Board.

Prior to BSC, Richner worked for GlaxoSmithKline (formerly SmithKline Beecham) in both London, England and Philadelphia, focusing on global pricing and economic issues for cardiopulmonary and diabetic drugs, publishing extensively. She was a member of the Global Health Policy Group (GHPG) consortium of leaders of health economics groups in the pharmaceutical and device industry. Richner has been an active member of the International Society of Pharmacoeconomics and Research (ISPOR) serving as a Board member for 2 years, founder of the US Medical Device Council of ISPOR, and Asia-Pacific Medical Device Council.

Richner has a master's degree in public health policy and administration from the University of Michigan where she is also a magna cum laude graduate of the bachelor's in science nursing program. Before her career in health economics and policy, she was a practicing dialysis and transplant nurse for 13 years at the University of Michigan Hospital and Northern Michigan Hospital.

### *Publications*

---

1. Leighton JA MD, Gralnek IM MD, **Richner R**, Lacey MJ, Papatheofanis FJ MD. Capsule Endoscopy in Suspected Small Bowel Crohn's Disease: Economic Impact of Disease Diagnosis and Treatment. Mayo Clinic. 2009.
2. Beusterien K, Leidy N, Sullivan E, **Richner R**, Muni NI. Integrating the patient's perspective into device evaluation trials. Value Health. 2006 Nov-Dec.
3. Halpern MT, Schmier JK, **Richner R**, Guo C, Togias A. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma. 2004 Feb;41(1):117-26.
4. **Richner R**. A proactive approach to reimbursement in the era of drug-eluting stents. J Cardiovasc Manag. 2002 Sep-Oct;13(5):32-3.



---

CONFIDENTIAL

---

5. Vera-Llonch M, Menzin J, **Richner RE**, Oster G. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program. *Ann Pharmacother*. 2001 Jul-Aug;35(7-8):846-51.
6. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, **Richner R**, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. *J Am Coll Cardiol*. 2001 May;37(6):1692-9.
7. Halpern M, Schmier J, **Richner R**, Toggias A. Antimicrobial treatment patterns, resource utilization, and charges associated with acute sinusitis in asthma patients. *Am J Health Syst Pharm*. 2000 May 1;57(9):875-81.
8. Delea TE, Vera-Llonch M, **Richner RE**, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. *Am J Cardiol*. 1999 Mar 15;83(6):890-6.
9. Menzin J, Colditz GA, Regan MM, **Richner RE**, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. *Arch Intern Med*. 1995 Apr 10;155(7):757-64.
10. Menzin J, **Richner R**, Huse D, Colditz GA, Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. *Ann Pharmacother*. 1994 Feb;28(2):271-5.
11. Menzin J, Huse DM, **Richner R**, Oster G. Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumonia. *Pharmacoeconomics*. 1992 Aug;2(2):171-7.
12. Picard VT, Sayers MH, Spinowitz BS, **Richner RE**. Transfusion therapy: associated risks and alternative approaches. *ANNA J*. 1990 Dec;17(6):457-64.
13. Deniston OL, Luscombe FA, Buesching DP, **Richner RE**, Spinowitz BS. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients. *ASAIO Trans*. 1990 Jul-Sep;36(3):M157-60.